SEARCH

SEARCH BY CITATION

References

  • 1
    Dinarello, C. A., IL-1: discoveries, controversies and future directions. Eur. J. Immunol. 2010. 40: 599606.
  • 2
    Dinarello, C. A., Renfer, L. and Wolff, S. M., Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc. Natl. Acad. Sci. USA 1977. 74: 46244627.
  • 3
    Rosenwasser, L. J., Dinarello, C. A. and Rosenthal, A. S., Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J. Exp. Med. 1979. 150: 709714.
  • 4
    Dinarello, C. A., Interleukin-1 and the pathogenesis of the acute-phase response. N. Engl. J. Med. 1984. 311: 14131418.
  • 5
    Lomedico, P. T., Gubler, R., Hellmann, C. P., Dukovich, M., Giri, J. G., Pan, Y. E., Collier, K. et al., Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 1984. 312: 458462.
  • 6
    Auron, P. E., Webb, A. C., Rosenwasser, L. J., Mucci, S. F., Rich, A., Wolff, S. M. and Dinarello, C. A., Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc. Natl. Acad. Sci. USA 1984. 81: 79077911.
  • 7
    Dinarello, C. A., Rosenwasser, L. J. and Wolff, S. M., Demonstration of a circulating suppressor factor of thymocyte proliferation during endotoxin fever in humans. J. Immunol. 1981. 127: 25172519.
  • 8
    Arend, W. P., Joslin, F. G. and Massoni, R. J., Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J. Immunol. 1985. 134: 38683875.
  • 9
    Seckinger, P., Lowenthal, J. W., Williamson, K., Dayer, J. M. and MacDonald, H. R., A urine inhibitor of interleukin 1 activity that blocks ligand binding. J. Immunol. 1987. 139: 15461549.
  • 10
    McDermott, M. F., Aksentijevich, I., Galon, J., McDermott, E. M., Ogunkolade, B. W., Centola, M., Mansfield, E. et al., Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999. 97: 133144.
  • 11
    Simon, A., Bodar, E. J., van der Hilst, J. C. H., Van der Meer, J. W., Fiselier, T. J. W., Cuppen, M. P. J. M. and Drenth, J. P. H., Beneficial response to interleukin-1 receptor antagonist in TRAPS. Am. J. Med. 2004. 117: 208210.
  • 12
    Gattorno, M., Pelagatti, M. A., Meini, A., Obici, L., Barcellona, R., Federici, S., Buoncompagni, A. et al., Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008. 58: 15161520.
  • 13
    Nedjai, B., Hitman, G. A., Quillinan, N., Coughlan, R. J., Church, L., McDermott, M. F. and Turner, M. D., Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2009. 60: 619625.
  • 14
    Masters, S. L., Simon, A., Aksentijevich, I. and Kastner, D. L., Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 2009. 27: 621668.
  • 15
    Hoffman, H. M., Wanderer, A. A. and Broide, D. H., Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J. Allergy Clin. Immunol. 2001. 108: 615620.
  • 16
    Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N. and Tschopp, J., NALP3 forms an IL-1β processing inflammasome with increased activity in Muckle–Wells auto-inflammatory disorder. Immunity 2004. 20: 319325.
  • 17
    Hoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P. et al., Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008. 58: 24432452.
  • 18
    Tschopp, J., Mitochondria: Sovereign of inflammation? Eur. J. Immunol. 2011. 41: 11961202.
  • 19
    Gattorno, M., Tassi, S., Carta, S., Delfino, L., Ferlito, F., Pelagatti, M. A., D'Osualdo, A. et al., Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 2007. 56: 31383148.
  • 20
    Gattorno, M., Piccini, A., Lasiglie, D., Tassi, S., Brisca, G., Carta, S., Delfino, L. et al., The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008. 58: 15051515.
  • 21
    Rosengren, S., Mueller, J. L., Anderson, J. P., Niehaus, B. L., Misaghi, A., Anderson, S., Boyle, D. L. and Hoffman, H. M., Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia. J. Allergy Clin. Immunol. 2007. 119: 991996.
  • 22
    Pascual, V., Allantaz, F., Arce, E., Punaro, M. and Banchereau, J., Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 2005. 201: 14791486.
  • 23
    Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J. et al., Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 2006. 355: 581592.
  • 24
    Netea, M. G., Nold-Petry, C. A., Nold, M. F., Joosten, L. A., Opitz, B., van der Meer, J. H., van de Veerdonk, F. L. et al., Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009. 113: 23242335.
  • 25
    Okamoto, M., Liu, W., Luo, Y., Tanaka, A., Cai, X., Norris, D. A., Dinarello, C. A. and Fujita, M., Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J. Biol. Chem. 2009. 285: 64776488.
  • 26
    Perregaux, D. G., McNiff, P., Laliberte, R., Conklyn, M. and Gabel, C. A., ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood. J. Immunol. 2000. 165: 46154623.
  • 27
    Joosten, L. A., Netea, M. G., Mylona, E., Koenders, M. I., Malireddi, R. K., Oosting, M., Stienstra, R. et al., Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 2010. 62: 32373248.
  • 28
    Dinarello, C. A., Ikejima, T., Warner, S. J., Orencole, S. F., Lonnemann, G., Cannon, J. G. and Libby, P., Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J. Immunol. 1987. 139: 19021910.
  • 29
    Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X. et al., Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 2009. 360: 24162425.
  • 30
    So, A., De Meulemeester, M., Pikhlak, A., Yucel, A. E., Richard, D., Murphy, V., Arulmani, U. et al., Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010. 62: 30643076.
  • 31
    Chen, C. J., Kono, H., Golenbock, D., Reed, G., Akira, S. and Rock, K. L., Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 2007. 13: 851856.
  • 32
    Cohen, I., Rider, P., Carmi, Y., Braiman, A., Dotan, S., White, M. R., Voronov, E. et al., Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc. Natl. Acad. Sci. USA 2010. 107: 25742579.
  • 33
    Kaplanski, G., Farnarier, C., Kaplanski, S., Porat, R., Shapiro, L., Bongrand, P. and Dinarello, C. A., Interleukin-1 induces interleukin-8 from endothelial cells by a juxacrine mechanism. Blood 1994. 84: 42424248.
  • 34
    Kaspar, R. L. and Gehrke, L., Peripheral blood mononuclear cells stimulated with C5a or lipopolysaccharide to synthesize equivalent levels of IL-1β mRNA show unequal IL-1β protein accumulation but similar polyribosome profiles. J. Immunol. 1994. 153: 277286.
  • 35
    Schindler, R., Clark, B. D. and Dinarello, C. A., Dissociation between interleukin-1β mRNA and protein synthesis in human peripheral blood mononuclear cells. J. Biol. Chem. 1990. 265: 1023210237.
  • 36
    Schindler, R., Gelfand, J. A. and Dinarello, C. A., Recombinant C5a stimulates transcription rather than translation of IL-1 and TNF; cytokine synthesis induced by LPS, IL-1 or PMA. Blood 1990. 76: 16311638.
  • 37
    Horai, R., Saijo, S., Tanioka, H., Nakae, S., Sudo, K., Okahara, A., Ikuse, T. et al., Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 2000. 191: 313320.
  • 38
    Nicklin, M. J., Hughes, D. E., Barton, J. L., Ure, J. M. and Duff, G. W., Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J. Exp. Med. 2000. 191: 303312.
  • 39
    Aksentijevich, I., Masters, S. L., Ferguson, P. J., Dancey, P., Frenkel, J., van Royen-Kerkhoff, A., Laxer, R. et al., An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 2009. 360: 24262437.
  • 40
    Reddy, S., Jia, S., Geoffrey, R., Lorier, R., Suchi, M., Broeckel, U., Hessner, M. J. and Verbsky, J., An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 2009. 360: 24382444.
  • 41
    Colotta, F., Re, F., Muzio, M., Bertini, R., Polentarutti, N., Sironi, M., Giri, J. et al., Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993. 261: 472475.
  • 42
    Schindler, R., Ghezzi, P. and Dinarello, C. A., IL-1 induces IL-1. IV. IFN-gamma suppresses IL-1 but not lipopolysaccharide-induced transcription of IL-1. J. Immunol. 1990. 144: 22162222.
  • 43
    Guarda, G., Braun, M., Staehli, F., Tardivel, A., Mattmann, C., Forster, I., Farlik, M. et al., Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011. 34: 213223.
  • 44
    Hoffman, H. M., Rosengren, S., Boyle, D. L., Cho, J. Y., Nayar, J., Mueller, J. L., Anderson, J. P. et al., Prevention of cold-associated acute inflammation in familail cold autoinflammatory syndrome by interleukin-1 receptor antagonist prevents. Lancet 2004. 364: 17791785.
  • 45
    Hawkins, P. N., Lachmann, H. J. and McDermott, M. F., Interleukin-1 receptor antagonist in the Muckle–Wells syndrome. N. Engl. J. Med. 2003. 348: 25832584.
  • 46
    Kitley, J. L., Lachmann, H. J., Pinto, A. and Ginsberg, L., Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology 2010. 74: 12671270.
  • 47
    Dinarello, C. A., Wolff, S. M., Goldfinger, S. E., Dale, D. C. and Alling, D. W., Colchicine therapy for familial Mediterranean fever – a double blind trial. N. Engl. J. Med. 1974. 291: 934937.
  • 48
    Hennig, S., Bayegan, K., Uffmann, M., Thalhammer, F. and Winkler, S., Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra-case report and review. Rheumatol. Int. 2011, in press.
  • 49
    Nedjai, B., Quillinan, N., Coughlan, R. J., Church, L., McDermott, M. F., Hitman, G. A. and Turner, M. D., Lessons from anti-TNF biologics: infliximab failure in a TRAPS family with the T50 M mutation in TNFRSF1A. Adv. Exp. Med. Biol. 2011. 691: 409419.
  • 50
    Dinarello, C. A., Cannon, J. G., Wolff, S. M., Bernheim, H. A., Beutler, B., Cerami, A., Figari, I. S. et al., Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J. Exp. Med. 1986. 163: 14331450.
  • 51
    Vaitla, P. M., Radford, P. M., Tighe, P. J., Powell, R. J., McDermott, E. M., Todd, I. and Drewe, E., Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum. 2011. 63: 11511155.
  • 52
    Bresnihan, B., Newmark, R. D., Robbins, S., McCabe, D. P. and Genant, H. K., Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomized controlled cohort of patients with rheumatoid arthritis. Arthritis Rheum. 2000. 43: S289.
  • 53
    Genant, H. K., Bresnihan, B., Ng, E., Robbins, S., Newmark, R. D. and McCabe, D., Treatment with anakinra reduces the rate of joint destruction and shows accelerated benefit in the secon 6 months of treatment for patients with rheumatoid arthritis. Ann. Rheum. Dis. 2001. 40: 169 (abs).
  • 54
    Joosten, L. A., Helsen, M. M., Saxne, T., van De Loo, F. A., Heinegard, D. and van Den Berg, W. B., IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J. Immunol. 1999. 163: 50495055.
  • 55
    Abramson, S. B. and Amin, A., Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 2002. 41: 972980.
  • 56
    Bresnihan, B. and Cobby, M., Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) 2003. 42: ii2228.
  • 57
    Mertens, M. and Singh, J. A., Anakinra for rheumatoid arthritis: a systematic review. J. Rheumatol. 2009. 36: 11181125.
  • 58
    Hess, A., Axmann, R., Rech, J., Finzel, S., Heindl, C., Kreitz, S., Sergeeva, M. et al., Blockade of TNF-{alpha} rapidly inhibits pain responses in the central nervous system. Proc. Natl. Acad. Sci. USA 2011. 108: 37313736.
  • 59
    Jung, N., Hellmann, M., Hoheisel, R., Lehmann, C., Haase, I., Perniok, A., Hallek, M. and Rubbert, A., An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin. Rheumatol. 2011. 29: 11691173.
  • 60
    Fitzgerald, A. A., Leclercq, S. A., Yan, A., Homik, J. E. and Dinarello, C. A., Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005. 52: 17941803.
  • 61
    Horneff, G., Schmeling, H., Biedermann, T., Foeldvari, I., Ganser, G., Girschick, H. J., Hospach, T. et al., The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. 2004. 63: 16381644.
  • 62
    Aronson, I. K. and Worobec, S. M., Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview. Dermatol. Ther. 2010. 23: 389402.
  • 63
    Behrens, E. M., Kreiger, P. A., Cherian, S. and Cron, R. Q., Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J. Rheumatol. 2006. 33: 20812084.
  • 64
    Bruck, N., Suttorp, M., Kabus, M., Heubner, G., Gahr, M. and Pessler, F., Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J. Clin. Rheumatol. 2010. 17: 2327.
  • 65
    Mazodier, K., Marin, V., Novick, D., Farnarier, C., Robitail, S., Schleinitz, N., Veit, V. et al., Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005. 106: 34833489.
  • 66
    Novick, D., Kim, S.-H., Fantuzzi, G., Reznikov, L., Dinarello, C. A. and Rubinstein, M., Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999. 10: 127136.
  • 67
    Joosten, L. A., Smeets, R. L., Koenders, M. I., van den Bersselaar, L. A., Helsen, M. M., Oppers-Walgreen, B., Lubberts, E. et al., Interleukin-18 promotes joint inflammation and induces interleukin-1-driven cartilage destruction. Am. J. Pathol. 2004. 165: 959967.
  • 68
    Fernandes, J. C., Martel-Pelletier, J. and Pelletier, J. P., The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002. 39: 237246.
  • 69
    Chevalier, X., Goupille, P., Beaulieu, A. D., Burch, F. X., Bensen, W. G., Conrozier, T., Loeuille, D. et al., Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009. 61: 344352.
  • 70
    Brown, C. A., Toth, A. P. and Magnussen, B., Clinical benefits of intra-articular anakinra for arthrofibrosis. Orthopedics 2011. 33: 877.
  • 71
    Wood, D. D., Ihrie, E. J., Dinarello, C. A. and Cohen, P. L., Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum. 1983. 26: 975983.
  • 72
    Duff, G. W., Atkins, E. and Malawista, S. E., The fever of gout: urate crystals activate endogenous pyrogen production from human and rabbit mononuclear phagocytes. Trans. Assoc. Am. Physicians 1983. 96: 234245.
  • 73
    Chen, C. J., Shi, Y., Hearn, A., Fitzgerald, K., Golenbock, D., Reed, G., Akira, S. and Rock, K. L., MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J. Clin. Invest. 2006. 116: 22622271.
  • 74
    Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. and Tschopp, J., Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006. 440: 237241.
  • 75
    Giamarellos-Bourboulis, E. J., Mouktaroudi, M., Bodar, E., van der Ven, J., Kullberg, B. J., Netea, M. G. and van der Meer, J. W., Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process. Ann. Rheum. Dis. 2009. 68: 273278.
  • 76
    Joosten, L. A., Netea, M. G., Fantuzzi, G., Koenders, M. I., Helsen, M. M., Sparrer, H., Pham, C. T. et al., Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum. 2009. 60: 36513662.
  • 77
    Singh, D. and Huston, K. K., IL-1 inhibition with anakinra in a patient with refractory gout. J. Clin. Rheumatol. 2009. 15: 366.
  • 78
    So, A., De Smedt, T., Revaz, S. and Tschopp, J., A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 2007. 9: R28.
  • 79
    Terkeltaub, R., Update on gout: new therapeutic strategies and options. Nat. Rev. Rheumatol. 2010. 6: 3038.
  • 80
    Terkeltaub, R., Sundy, J. S., Schumacher, H. R., Murphy, F., Bookbinder, S., Biedermann, S., Wu, R. et al., The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann. Rheum. Dis. 2009. 68: 16131617.
  • 81
    Fiehn, C. and Zeier, M., Successful treatment of chronic tophaceous gout with infliximab (Remicade). Rheumatol. Int. 2006. 26: 274276.
  • 82
    Mandrup-Poulsen, T., Bendtzen, K., Nerup, J., Dinarello, C. A., Svenson, M. and Nielsen, J. H., Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 1986. 29: 6367.
  • 83
    Bendtzen, K., Mandrup-Poulsen, T., Nerup, J., Nielsen, J. H., Dinarello, C. A. and Svenson, M., Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986. 232: 15451547.
  • 84
    Donath, M. Y., Storling, J., Berchtold, L. A., Billestrup, N. and Mandrup-Poulsen, T., Cytokines and beta-cell biology: from concept to clinical translation. Endocr. Rev. 2008. 29: 334350.
  • 85
    Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N. et al., Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 2002. 110: 851860.
  • 86
    Stienstra, R., Joosten, L. A., Koenen, T., van Tits, B., van Diepen, J. A., van den Berg, S. A., Rensen, P. C. et al., The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 2011. 12: 593605.
  • 87
    Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C. et al., Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat. Immunol. 2010. 11: 897904.
  • 88
    Masters, S. L. and O'Neill, L. A., Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. Trends Mol. Med. 2011, in press.
  • 89
    Vandanmagsar, B., Youm, Y. H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E. et al., The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 2011. 17: 179188.
  • 90
    Larsen, C. M., Faulenbach, M., Vaag, A., Volund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T. and Donath, M. Y., Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007. 356: 15171526.
  • 91
    Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y. and Mandrup-Poulsen, T., Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009. 32: 16631668.
  • 92
    Donath, M. Y., Weder, C., Brunner, A., Keller, C., Whitemore, J., Der, K., Zayed, H. et al., XOMA 052, a potential disease modifying anti-1L-1beta antibody, shows sustained HbA1c reductions 3 months after a single injection with no increases in safety parameters in subjects with type 2 diabetes. Diabetes 2009. 58: A30.
  • 93
    Donath, M. Y., Boni-Schnetzler, M., Ellingsgaard, H. and Ehses, J. A., Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009. 24: 325331.
  • 94
    Abbate, A., Van Tassell, B. W., Seropian, I. M., Toldo, S., Robati, R., Varma, A., Salloum, F. N. et al., Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur. J. Heart Fail. 2010. 12: 319322.
  • 95
    Abbate, A., Kontos, M. C., Grizzard, J. D., Biondi-Zoccai, G. G., Van Tassell, B. W., Robati, R., Roach, L. M. et al., Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction. Am. J. Cardiol. 2010. 105: 13711377.
  • 96
    Abbate, A., Salloum, F. N., Vecile, E., Das, A., Hoke, N. N., Straino, S., Biondi-Zoccai, G. G. et al., Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008. 117: 26702683.
  • 97
    Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R. et al., Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 2007. 356: 25822590.
  • 98
    Torcia, M., Lucibello, M., Vannier, E., Fabiani, S., Miliani, A., Guidi, G., Spada, O. et al., Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. Exp. Hematol. 1996. 24: 868874.
  • 99
    Lust, J. A. and Donovan, K. A., The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol. Oncol. Clin. North Am. 1999. 13: 11171125.
  • 100
    Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Dispenzieri, A., Gertz, M. A., Witzig, T. E., Kumar, S. et al., Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1beta-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin. Proc. 2009. 84: 114122.
  • 101
    Lipsker, D., The Schnitzler syndrome. Orphanet J. Rare Dis. 2010. 5: 38.
  • 102
    Nishimoto, N., Sasai, M., Shima, Y., Nakagawa, M., Matsumoto, T., Shirai, T., Kishimoto, T. and Yoshizaki, K., Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000. 95: 5661.
  • 103
    El-Osta, H., Janku, F. and Kurzrock, R., Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). Mol. Cancer Ther. 2011. 9: 14851488.
  • 104
    Dinarello, C. A., Biological basis for interleukin-1 in disease. Blood 1996. 87: 20952147.
  • 105
    Nemunaitis, J., Ross, M., Meisenberg, B., O'Reilly, R., Lilleby, K., Buckner, C. D., Appelbaum, F. R. et al., Phase I study of recombinant human interleukin-1 beta (rhIL-1 beta) in patients with bone marrow failure. Bone Marrow Transplant. 1994. 14: 583588.
  • 106
    Triozzi, P. L., Kim, J. A., Martin, E. W., Young, D. C., Benzies, T. and Villasmil, P. M., Phase I trial of escalating doses of interleukin-1 beta in combination with a fixed dose of interleukin-2. J. Clin. Oncol. 1995. 13: 482489.
  • 107
    Vadhan-Raj, S., Kudelka, A. P., Garrison, L., Gano, J., Edwards, C. L., Freedman, R. S. and Kavanagh, J. J., Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J. Clin. Oncol. 1994. 12: 707714.
  • 108
    Verschraegen, C. F., Kudelka, A. P., Termrungruanglert, W., de Leon, C. G., Edwards, C. L., Freedman, R. S., Kavanagh, J. J. and Vadhan-Raj, S., Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease. Eur. J. Cancer 1996. 32A: 16091611.
  • 109
    Curti, B. D., Urba, W. J., Longo, D. L., Janik, J. E., Sharfman, W. H., Miller, L. L., Cizza, G. et al., Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer. J. Immunother. Emphasis Tumor Immunol. 1996. 19: 142148.
  • 110
    Janik, J. E., Miller, L. L., Longo, D. L., Powers, G. C., Urba, W. J., Kopp, W. C., Gause, B. L. et al., Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma. J. Natl. Cancer Inst. 1996. 88: 4449.
  • 111
    Kopp, W. C., Urba, W. J., Rager, H. C., Alvord, W. G., Oppenheim, J. J., Smith, J. W., 2nd and Longo, D. L., Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer. Clin. Cancer Res. 1996. 2: 501506.
  • 112
    Smith, J. W., 2nd., Longo, D. L., Alvord, W. G., Janik, J. E., Sharfman, W. H., Gause, B. L., Curti, B. D. et al., The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. N. Engl. J. Med. 1993. 328: 756761.
  • 113
    Tilg, H., Trehu, E., Shapiro, L., Pape, D., Atkins, M. B., Dinarello, C. A. and Mier, J. W., Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans. Cytokine 1994. 6: 215219.
  • 114
    Mitroulis, I., Papadopoulos, V. P., Konstantinidis, T. and Ritis, K., Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth. J. Med. 2008. 66: 489491.
  • 115
    Calligaris, L., Marchetti, F., Tommasini, A. and Ventura, A., The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur. J. Pediatr. 2008. 167: 695696.
  • 116
    Meinzer, U., Quartier, P., Alexandra, J. F., Hentgen, V., Retornaz, F. and Kone-Paut, I., Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin. Arthritis Rheum. 2011, in press.
  • 117
    Ozen, S., Bilginer, Y., Ayaz, N. A. and Calguneri, M., Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J. Rheumatol. 2011, in press.
  • 118
    Petropoulou, A. D., Robin, M., Socie, G. and Galicier, L., Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinra. Transplantation 2011. 90: 102103.
  • 119
    Brenner, M., Ruzicka, T., Plewig, G., Thomas, P. and Herzer, P., Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br. J. Dermatol. 2009. 161: 11991201.
  • 120
    Dierselhuis, M. P., Frenkel, J., Wulffraat, N. M. and Boelens, J. J., Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology 2005. 44: 406408.
  • 121
    Yu, J. W., Fernandes-Alnemri, T., Datta, P., Wu, J., Juliana, C., Solorzano, L., McCormick, M. et al., Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol. Cell 2007. 28: 214227.
  • 122
    Bodar, E. J., Simon, A., de Visser, M. and van der Meer, J. W., Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). Neth. J. Med. 2009. 67: 302305.
  • 123
    Kolivras, A., Theunis, A., Ferster, A., Lipsker, D., Sass, U., Dussart, A. and Andre, J., Cryopyrin-associated periodic syndrome: an autoinflammatory disease manifested as neutrophilic urticarial dermatosis with additional perieccrine involvement. J. Cutan. Pathol. 2011. 38: 202208.
  • 124
    Kuemmerle-Deschner, J. B., Tyrrell, P. N., Koetter, I., Wittowski, H., Bialkowski, A., Tzaribachev, N., Lohse, P. et al., Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle–Wells syndrome. Arthritis Rheum. 2011. 63: 840849.
  • 125
    Lepore, L., Paloni, G., Caorsi, R., Alessio, M., Rigante, D., Ruperto, N., Cattalini, M. et al., Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J. Pediatr. 2010. 157: 310315 e311.
  • 126
    Neven, B., Marvillet, I., Terrada, C., Ferster, A., Boddaert, N., Couloignier, V., Pinto, G. et al., Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2011. 62: 258267.
  • 127
    Bodar, E. J., van der Hilst, J. C., Drenth, J. P., van der Meer, J. W. and Simon, A., Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth. J. Med. 2005. 63: 260264.
  • 128
    Rigante, D., Ansuini, V., Bertoni, B., Pugliese, A. L., Avallone, L., Federico,G. and Stabile, A., Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol. Int. 2006. 27: 97100.
  • 129
    Cailliez, M., Garaix, F., Rousset-Rouviere, C., Bruno, D., Kone-Paut, I., Sarles, J., Chabrol, B. and Tsimaratos, M., Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J. Inherit. Metab. Dis. 2006. 29: 763.
  • 130
    Bodar, E., Kuikk, L., Drenth, J. P., van der Meer, J. H., Simon, A. and Frenkel, J., On demand anakinra treatment is effective in mevalonate kinase deficiency. Clin Exp Immunol 2011, in press.
  • 131
    Lahiri, M. and Teng, G. G., A case of refractory adult-onset Still's disease treated with anakinra. Int. J. Rheum. Dis. 2010. 13: e36e41.
  • 132
    Moulis, G., Sailler, L., Astudillo, L., Pugnet, G. and Arlet, P., May anakinra be used earlier in adult onset Still disease? Clin. Rheumatol. 29: 11991200.
  • 133
    Naumann, L., Feist, E., Natusch, A., Langen, S., Krause, A., Buttgereit, F. and Burmester, G. R., IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann. Rheum. Dis. 2010. 69: 466467.
  • 134
    Lequerre, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., Kone-Paut, I. et al., Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 2008. 67: 302308.
  • 135
    Ohlsson, V., Baildam, E., Foster, H., Jandial, S., Pain, C., Strike, H. and Ramanan, A. V., Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 2008. 47: 555556.
  • 136
    Mirkinson, L. J., Nagle, D., Kadom, N. and Jones, O. Y., Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis. J. Clin. Rheumatol. 2006. 12: 8386.
  • 137
    Bagnari, V., Colina, M., Ciancio,G., Govoni, M. and Trotta, F., Adult-onset Still's disease. Rheumatol. Int. 2010. 30: 855862.
  • 138
    Raffeiner, B., Botsios, C., Dinarello, C. A., Ometto, F., Punzi, L. and Ramonda, R., Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine 2011. 78: 100101.
  • 139
    Nigrovic, P. A., Mannion, M., Prince, F. H., Zeft, A., Rabinovich, C. E., van Rossum, M. A., Cortis, E. et al., Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011. 63: 545555.
  • 140
    Quartier, P., Allantaz, F., Cimaz, R., Pillet, P., Messiaen, C., Bardin, C., Bossuyt, X. et al., A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 2011. 70: 747754.
  • 141
    De Koning, H. D., Bodar, E. J., Simon, A., van der Hilst, J. C. H., Netea, M. G. and Van der Meer, J. W., Beneficial reponse to anakinra and thalidomide in Schnitzler's syndrome. Ann. Rheum. Dis. 2006. 65: 542544.
  • 142
    Eiling, E., Moller, M., Kreiselmaier, I., Brasch, J. and Schwarz, T., Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J. Am. Acad. Dermatol. 2007. 57: 361364.
  • 143
    Adam, Z., Krejci, M., Pour, L., Neubauer, J., Prasek, J. and Hajek, R., [Schnitzler syndrome – report on a fourteen-year course of the disease and an overview of information on the disease]. Vnitr Lek 2008. 54: 11401153.
  • 144
    Sacre, K., Brihaye, B., Lidove, O., Papo, T., Pocidalo, M. A., Cuisset, L. and Dode, C., Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. J. Rheumatol. 2008. 35: 357358.
  • 145
    Picco, P., Brisca, G., Traverso, F., Loy, A., Gattorno, M. and Martini, A., Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum. 2009. 60: 264268.
  • 146
    Cantarini, L., Lucherini, O. M., Cimaz, R. and Galeazzi, M., Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clin. Exp. Rheumatol. 2010. 28: 802.
  • 147
    Kelly, A. and Ramanan, A. V., A case of macrophage activation syndrome successfully treated with anakinra. Nat. Clin. Pract. Rheumatol. 2008. 4: 615620.
  • 148
    Chou, R. C., Dinarello, C. A., Ferry, J. A. and Dal Cin, P., A 36-year-old woman with recurrent high-grade fevers, hypotension, and hypertriglyceridemia. Arthritis Care Res. 2010. 62: 137140.
  • 149
    Botsios, C., Sfriso, P., Punzi, L. and Todesco, S., Non-complementaemic urticarial vasculitis: successful treatment with the IL-1 receptor antagonist, anakinra. Scand. J. Rheumatol. 2007. 36: 236237.
  • 150
    Furlan, A., Botsios, C., Ruffatti, A., Todesco, S. and Punzi, L., Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine 2008. 75: 366367.
  • 151
    Chauffier, K., London, J., Beaudouin, C. and Fautrel, B., [Indications of anakinra]. Presse Med. 2009. 38: 799807.
  • 152
    Botsios, C., Sfriso, P., Furlan, A., Punzi, L. and Dinarello, C. A., Reistant Behçet disease responsive to anakinra. Ann. Intern. Med. 2008. 149: 284286.
  • 153
    Gul, A., Artim-Esen, B., Solinger, A. M., Giustino, L., Dinarello, C. and Tugal-Tutkun, I., Safe, rapid-onset, and sustained biological activity of IL-1 regulating antibody XOMA 052 in resistant uveitis of Behcet's idsease: results of a pilot trial. Arthritis Rheum. 2010. 62: 1308 (abs).
  • 154
    Aouba, A., Georgin-Lavialle, S., Pagnoux, C., Martin Silva, N., Renand, A., Galateau-Salle, F., Le Toquin, S. et al., Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease. Blood 2010. 116: 40704076.
  • 155
    Colina, M., Pizzirani, C., Khodeir, M., Falzoni, S., Bruschi, M., Trotta, F. and Di Virgilio, F., Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. Rheumatology (Oxford) 2010. 49: 14161418.
  • 156
    Stojanova, S., Lapidusa, S., Chitkara, P., Feder, F., Salazarf, J. C., Fleisher, T. A., Brown, M. R. et al., Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc. Natl. Acad. Sci. USA 2011, in press.
  • 157
    Gratton, S. B., Scalapino, K. J. and Fye, K. H., Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum. 2009. 61: 12681270.
  • 158
    McGonagle, D., Tan, A. L., Shankaranarayana, S., Madden, J., Emery, P. and McDermott, M. F., Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann. Rheum. Dis. 2007. 66: 16831684.